Use of ipilimumab in the treatment of melanoma

Utkarsh H. Acharya, Joanne M. Jeter

Research output: Contribution to journalReview article

20 Scopus citations

Abstract

Ipilimumab is a monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4 that has been approved by the US Food and Drug Administration for the treatment of metastatic melanoma. Phase III trials have demonstrated an overall survival benefit with its use when compared with standard treatments and other investigational therapies. However, the drug poses a notable challenge, given its propensity for toxicity, and requires close surveillance when administered in clinical practice. This review discusses the mechanism of action for ipilimumab, its preclinical data, and the clinical trials that led to its approval by the Food and Drug Administration in 2011.

Original languageEnglish (US)
Pages (from-to)21-27
Number of pages7
JournalClinical Pharmacology: Advances and Applications
Volume5
Issue numberSUPPL. 1
DOIs
StatePublished - Aug 9 2013

    Fingerprint

Keywords

  • Immunotherapy
  • Ipilimumab
  • Melanoma

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this